FDA approves Hibsago, a new shot-based treatment for chronic hepatitis B
Published
GSK's bepirovirsen is a 24-week course of injections added to standard antiviral pills for certain adults without cirrhosis. In studies, 19% of patients cleared signs of the virus well enough to be considered functionally cured, versus none on placebo.
Source: Contagion Live
This is a plain-language summary. Read the original source for full details.